ET Pharma

Novartis strikes up to $7.8 billion mRNA deal with China's Abogen

Oct 3, 2026, 2:02 AM

Translate article text

Choose a language and wait for the translated text.

Novartis will gain exclusive rights to Abogen's experimental drug, ABO2203, and options to license other therapies based on Abogen's RNA technology. It will also have the option to license additional experimental medicines developed using Abogen's RNA platform.

Novartis strikes up to $7.8 billion mRNA deal with China&#039;s Abogen

Novartis strikes up to $7.8 billion mRNA deal with China's Abogen